CLL Roundup Lawsuit: What to Know

What CLL Roundup Claims Allege

Chronic lymphocytic leukemia, or CLL, is a slow-progressing cancer of the blood and bone marrow affecting white blood cells called lymphocytes, and is closely related to a form of non-Hodgkin lymphoma. A subset of the broader Roundup litigation specifically alleges that regular, long-term exposure to glyphosate, the herbicide active ingredient, caused CLL, alongside the larger body of Roundup cases centered on other blood cancers, most commonly non-Hodgkin lymphoma more generally.

The scientific support cited for these claims traces back to the World Health Organization International Agency for Research on Cancer, which classified glyphosate as probably carcinogenic to humans in 2015, based partly on studies suggesting an association with non-Hodgkin lymphoma and related blood cancers. Plaintiffs allege Monsanto, and later Bayer after it acquired Monsanto, knew or should have known about this risk but failed to adequately warn users. Bayer disputes that glyphosate causes cancer and continues to defend the safety of its products.

The Scale of the Litigation

As of March 2025, roughly 165,000 Roundup lawsuits had been filed nationwide, with a large portion consolidated in the federal MDL 2741 in the Northern District of California, alongside significant state court litigation. Multiple large jury verdicts have been returned in individual cases in recent years, including a 175 million dollar verdict for one plaintiff, reflecting how juries have responded when these cases have gone to trial, though verdicts like this are specific to individual cases and are not a guarantee of what any other case, including a CLL-specific claim, might receive.

A North Dakota law signed in April 2025 now shields Bayer from certain future glyphosate-related lawsuits filed in that state going forward, though it does not affect the tens of thousands of cases already pending nationwide in other states or federal court.

Two Major 2026 Developments That Affect CLL Claims Too

Two significant developments are unfolding that affect the Roundup litigation broadly, including CLL claims specifically, not just the non-Hodgkin lymphoma cases that make up the bulk of the docket. In February 2026, Bayer announced a proposed 7.25 billion dollar global settlement intended to resolve current and future Roundup claims across cancer types, though it has not received final court approval and faces pushback over its compensation structure and an unresolved jurisdictional dispute about consolidating it into the existing MDL.

Separately, in June 2026, the Supreme Court ruled in favor of Monsanto on a preemption question, holding that a specific Missouri failure-to-warn claim was preempted by federal pesticide law, a ruling that could significantly affect how failure-to-warn theories, the core legal theory behind most Roundup claims including CLL cases, are treated going forward in other pending litigation. Given how much is unfolding at once, a general summary of the litigation status can go stale quickly, and current, individualized legal advice is the only reliable way to understand where a specific CLL claim stands today.

How to Get Legal Help

If you developed CLL or another blood cancer after regular, long-term exposure to Roundup or another glyphosate-based herbicide, gather documentation of your exposure history, including how long and how often you used the product, along with your diagnosis records. Given the proposed global settlement and a major 2026 Supreme Court ruling both currently unfolding, an attorney experienced in this litigation can explain how these developments may affect your specific situation.

To follow any further developments, bookmark this page and subscribe to LawsuitWatch alerts.